Arcellx Inc.

18.60+0.5200+2.88%Vol 79.55K1Y Perf -
Jul 1st, 2022 16:00 DELAYED
BID15.62 ASK18.98
Open17.95 Previous Close18.08
Pre-Market- After-Market18.55
 - -  -0.05 -0.27%
Target Price
35.00 
Analyst Rating
Strong Buy 1.00
Potential %
88.17 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
60.19 
Earnings Rating
Market Cap814.42M 
Earnings Date
11th Aug 2022
Alpha-0.12 Standard Deviation0.20
Beta0.40 

Today's Price Range

17.9518.92

52W Range

6.0426.91

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
3.74%
1 Month
44.41%
3 Months
29.35%
6 Months
-
1 Year
-
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ACLX18.600.52002.88
AAPL138.932.21001.62
GOOG2 181.62-5.8300-0.27
MSFT259.582.75001.07
XOM87.551.91002.23
WFC39.920.75001.91
JNJ179.522.01001.13
FB196.640.99000.51
GE63.54-0.1300-0.20
JPM114.051.44001.28
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.95-1.56-64.21
Q04 2021-0.69-39.85-5 675.36
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Aug 2022
Estimated EPS Next Report-1.20
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume79.55K
Shares Outstanding43.79K
Shares Float25.72M
Trades Count1.67K
Dollar Volume1.47M
Avg. Volume332.34K
Avg. Weekly Volume257.76K
Avg. Monthly Volume515.80K
Avg. Quarterly Volume223.47K

Arcellx Inc. (NASDAQ: ACLX) stock closed at 18.6 per share at the end of the most recent trading day (a 2.88% change compared to the prior day closing price) with a volume of 79.55K shares and market capitalization of 814.42M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 78 people. Arcellx Inc. CEO is .

The one-year performance of Arcellx Inc. stock is %, while year-to-date (YTD) performance is %. ACLX stock has a five-year performance of %. Its 52-week range is between 6.035 and 26.91, which gives ACLX stock a 52-week price range ratio of 60.19%

Arcellx Inc. currently has a PE ratio of -6.00, a price-to-book (PB) ratio of 3.54, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -35.36%, a ROC of -37.95% and a ROE of -38.84%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Arcellx Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.20 for the next earnings report. Arcellx Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Arcellx Inc. is Strong Buy (1), with a target price of $35, which is +88.17% compared to the current price. The earnings rating for Arcellx Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arcellx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arcellx Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 50.76, ATR14 : 2.25, CCI20 : 24.11, Chaikin Money Flow : -0.02, MACD : 1.39, Money Flow Index : 31.11, ROC : 3.97, RSI : 59.74, STOCH (14,3) : 41.48, STOCH RSI : 0.81, UO : 58.09, Williams %R : -58.52), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arcellx Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Arcellx Inc.

Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

CEO:

Telephone: +1 240 327-0603

Address: 25 West Watkins Mill Road, Gaithersburg 20878, MD, US

Number of employees: 78

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

60%40%

Bearish Bullish

57%43%

News

Stocktwits